Good
Mostly Aligned
Patient Risk:
Low
Summary
Most evaluated claims were correctly marked as unsupported where the provided label excerpts contain no related information (e.g., therapeutic equivalence vs Singulair, pricing/coupons, generic approval status). However, the audit is incomplete because critical label elements (e.g., boxed warnings, contraindications, dosing/administration details, and key safety/adverse reaction content) were not assessed, so potential material omissions cannot be ruled out.
Category Scores
Accurate Statements
Generic montelukast is therapeutically equivalent to the brand (Singulair) for most patients.
absent (user evaluation marked as absent; provided excerpts do not state therapeutic equivalence/interchangeability vs Singulair).
Generic montelukast uses the same active ingredient (montelukast) as Singulair.
partially supported (11 DESCRIPTION identifies montelukast sodium as the active ingredient for montelukast products; no Singulair-specific comparison in provided excerpts).
Generic montelukast is approved as a generic by regulators.
absent (no provided label excerpt states regulatory generic approval status).
Differences between generic montelukast and Singulair, if any, are typically in inactive ingredients and formulation type (tablet vs. chewable).
absent (11 DESCRIPTION lists inactive ingredients for a tablet formulation but provides no Singulair comparison or 'typically' language).
Cash prices for generic montelukast can be lower with pharmacy discount programs or coupons even when not using insurance.
absent (no pricing/coupons/insurance information in provided excerpts).
Unsupported Statements
Contradictions
Important Omissions
The audit did not verify critical label elements that are safety-critical (e.g., boxed warnings, contraindications, dosing/administration instructions, major warnings/precautions including neuropsychiatric risk, and adverse reactions).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The specific evaluated claims were mostly marked as unsupported due to absence of supporting label excerpts; however, because critical safety label sections were not assessed, material omissions in the overall audit cannot be excluded.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Audit completeness: critical prescribing-information sections were not checked, so alignment to the full label is unverified.
Suggested Improvement
Include and score all relevant FDA label categories from the complete prescribing information (boxed warnings, contraindications, warnings/precautions, dosing/administration, adverse reactions, and specific population sections), and cite the corresponding sections for each claim.